TABLE 2.
RAN and RANBP2 gene polymorphisms with glioma susceptibility in Chinese children.
| Genotype | Cases (N = 191) | Controls (N = 248) | p a | Crude OR (95% CI) | p | Adjusted OR (95% CI) b | p b |
|---|---|---|---|---|---|---|---|
| RAN rs56109543 C>T (HWE = 0.447) | |||||||
| CC | 126 (65.97) | 178 (71.77) | 1.00 | 1.00 | |||
| CT | 58 (30.37) | 66 (26.61) | 1.24 (0.82–1.89) | 0.313 | 1.30 (0.85–1.99) | 0.221 | |
| TT | 7 (3.66) | 4 (1.61) | 2.47 (0.71–8.62) | 0.156 | 2.06 (0.58–7.31) | 0.266 | |
| Additive | 0.118 | 1.33 (0.93–1.91) | 0.119 | 1.34 (0.93–1.93) | 0.115 | ||
| Dominant | 65 (34.03) | 70 (28.23) | 0.191 | 1.31 (0.87–1.97) | 0.192 | 1.36 (0.90–2.04) | 0.150 |
| Recessive | 184 (96.34) | 244 (98.39) | 0.173 | 2.32 (0.67–8.05) | 0.185 | 1.92 (0.54–6.79) | 0.312 |
| RAN rs7132224 A>G (HWE = 0.799) | |||||||
| AA | 101 (52.88) | 141 (56.85) | 1.00 | 1.00 | |||
| AG | 78 (40.84) | 91 (36.69) | 1.20 (0.81–1.78) | 0.374 | 1.23 (0.83–1.84) | 0.305 | |
| GG | 12 (6.28) | 16 (6.45) | 1.05 (0.48–2.31) | 0.909 | 1.04 (0.47–2.31) | 0.923 | |
| Additive | 0.520 | 1.11 (0.81–1.50) | 0.520 | 1.12 (0.82–1.53) | 0.472 | ||
| Dominant | 90 (47.12) | 107 (43.15) | 0.406 | 1.17 (0.80–1.72) | 0.407 | 1.20 (0.82–1.76) | 0.344 |
| Recessive | 179 (93.72) | 232 (93.55) | 0.943 | 0.97 (0.45–2.11) | 0.943 | 0.95 (0.44–2.08) | 0.906 |
| RAN rs14035 C>T (HWE = 0.995) | |||||||
| CC | 120 (62.83) | 167 (67.34) | 1.00 | 1.00 | |||
| CT | 64 (33.51) | 73 (29.44) | 1.22 (0.81–1.84) | 0.341 | 1.27 (0.84–1.92) | 0.262 | |
| TT | 7 (3.66) | 8 (3.23) | 1.22 (0.43–3.45) | 0.711 | 1.22 (0.43–3.51) | 0.710 | |
| Additive | 0.352 | 1.18 (0.84–1.65) | 0.352 | 1.21 (0.85–1.70) | 0.288 | ||
| Dominant | 71 (37.17) | 81 (32.66) | 0.325 | 1.22 (0.82–1.81) | 0.325 | 1.26 (0.85–1.88) | 0.253 |
| Recessive | 184 (96.34) | 240 (96.77) | 0.802 | 1.14 (0.41–3.21) | 0.801 | 1.13 (0.40–3.22) | 0.816 |
| RANBP2 rs2462788 C>T (HWE = 0.465) | |||||||
| CC | 175 (91.62) | 226 (91.13) | 1.00 | 1.00 | |||
| CT | 16 (8.38) | 22 (8.87) | 0.94 (0.48–1.84) | 0.856 | 0.94 (0.48–1.84) | 0.856 | |
| TT | 0 (0.00) | 0 (0.00) | / | / | / | / | |
| Additive | 0.855 | 0.94 (0.48–1.84) | 0.856 | 0.94 (0.48–1.84) | 0.846 | ||
| Dominant | 16 (8.38) | 222 (8.87) | 0.855 | 0.94 (0.48–1.84) | 0.856 | 0.94 (0.48–1.84) | 0.856 |
| Combined effect of risk genotypes c | |||||||
| 0 | 97 (50.79) | 141 (56.85) | 0.266 | 1.00 | 1.00 | ||
| 1 | 24 (12.57) | 26 (10.48) | 1.34 (0.73–2.48) | 0.347 | 1.35 (0.73–2.50) | 0.346 | |
| 2 | 8 (4.19) | 11 (4.44) | 1.06 (0.41–2.73) | 0.908 | 1.11 (0.43–2.87) | 0.833 | |
| 3 | 62 (32.46) | 70 (28.23) | 1.29 (0.84–1.98) | 0.248 | 1.33 (0.86–2.05) | 0.196 | |
| 0 | 97 (50.79) | 141 (56.85) | 1.00 | 1.00 | |||
| 1–3 | 94 (49.21) | 107 (43.15) | 0.206 | 1.28 (0.87–1.87) | 0.206 | 1.31 (0.89–1.92) | 0.165 |
Abbreviations: CI, confidence interval; HWE, Hardy–Weinberg equilibrium; OR, odds ratio.
a
χ 2 test for genotype distributions between glioma patients and cancer‐free controls.
b
Adjusted for age and gender.
c
Risk genotypes were carriers with rs56109543 CT/TT, rs7132224 AG/GG, and rs14035 CT/TT genotypes.